The latest Novavax vaccine will only be avaliable to the elderly and those over the age of 12 with an underlying medical condition.

The approval of the vaccine, named Nuvaxovid, is contingent on the company conducting studies to assess potential links to various heart conditions.

However, Some of these investigations can be carried out using existing data sources.